BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 33681816)

  • 1. A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms.
    Guan Y; Tiwari AD; Phillips JG; Hasipek M; Grabowski DR; Pagliuca S; Gopal P; Kerr CM; Adema V; Radivoyevitch T; Parker Y; Lindner DJ; Meggendorfer M; Abazeed M; Sekeres MA; Mian OY; Haferlach T; Maciejewski JP; Jha BK
    Blood Cancer Discov; 2021 Mar; 2(2):146-161. PubMed ID: 33681816
    [No Abstract]   [Full Text] [Related]  

  • 2. TET-dioxygenase deficiency in oncogenesis and its targeting for tumor-selective therapeutics.
    Guan Y; Hasipek M; Tiwari AD; Maciejewski JP; Jha BK
    Semin Hematol; 2021 Jan; 58(1):27-34. PubMed ID: 33509440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TET2 mutation as prototypic clonal hematopoiesis lesion.
    Guarnera L; Jha BK
    Semin Hematol; 2024 Feb; 61(1):51-60. PubMed ID: 38431463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of TET dioxygenases in the regulation of both normal and pathological hematopoiesis.
    Joshi K; Zhang L; Breslin S J P; Kini AR; Zhang J
    J Exp Clin Cancer Res; 2022 Oct; 41(1):294. PubMed ID: 36203205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia.
    Rampal R; Alkalin A; Madzo J; Vasanthakumar A; Pronier E; Patel J; Li Y; Ahn J; Abdel-Wahab O; Shih A; Lu C; Ward PS; Tsai JJ; Hricik T; Tosello V; Tallman JE; Zhao X; Daniels D; Dai Q; Ciminio L; Aifantis I; He C; Fuks F; Tallman MS; Ferrando A; Nimer S; Paietta E; Thompson CB; Licht JD; Mason CE; Godley LA; Melnick A; Figueroa ME; Levine RL
    Cell Rep; 2014 Dec; 9(5):1841-1855. PubMed ID: 25482556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct and opposite effects of leukemogenic
    Fortin J; Chiang MF; Meydan C; Foox J; Ramachandran P; Leca J; Lemonnier F; Li WY; Gams MS; Sakamoto T; Chu M; Tobin C; Laugesen E; Robinson TM; You-Ten A; Butler DJ; Berger T; Minden MD; Levine RL; Guidos CJ; Melnick AM; Mason CE; Mak TW
    Proc Natl Acad Sci U S A; 2023 Jan; 120(4):e2208176120. PubMed ID: 36652477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TET2 as an epigenetic master regulator for normal and malignant hematopoiesis.
    Nakajima H; Kunimoto H
    Cancer Sci; 2014 Sep; 105(9):1093-9. PubMed ID: 25040794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.
    Solary E; Bernard OA; Tefferi A; Fuks F; Vainchenker W
    Leukemia; 2014 Mar; 28(3):485-96. PubMed ID: 24220273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1β/NLRP3 Inflammasome.
    Sano S; Oshima K; Wang Y; MacLauchlan S; Katanasaka Y; Sano M; Zuriaga MA; Yoshiyama M; Goukassian D; Cooper MA; Fuster JJ; Walsh K
    J Am Coll Cardiol; 2018 Feb; 71(8):875-886. PubMed ID: 29471939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Cell Type-Specific 5hmC Landscape and Dynamics of Healthy Human Hematopoiesis and TET2-Mutant Preleukemia.
    Nakauchi Y; Azizi A; Thomas D; Corces MR; Reinisch A; Sharma R; Cruz Hernandez D; Köhnke T; Karigane D; Fan A; Martinez-Krams D; Stafford M; Kaur S; Dutta R; Phan P; Ediriwickrema A; McCarthy E; Ning Y; Phillips T; Ellison CK; Guler GD; Bergamaschi A; Ku CJ; Levy S; Majeti R
    Blood Cancer Discov; 2022 Jul; 3(4):346-367. PubMed ID: 35532363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations.
    Lin TL; Nagata Y; Kao HW; Sanada M; Okuno Y; Huang CF; Liang DC; Kuo MC; Lai CL; Lee EH; Shih YS; Tanaka H; Shiraishi Y; Chiba K; Lin TH; Wu JH; Miyano S; Ogawa S; Shih LY
    Haematologica; 2014 Jan; 99(1):28-36. PubMed ID: 23996483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression.
    Cimmino L; Dolgalev I; Wang Y; Yoshimi A; Martin GH; Wang J; Ng V; Xia B; Witkowski MT; Mitchell-Flack M; Grillo I; Bakogianni S; Ndiaye-Lobry D; Martín MT; Guillamot M; Banh RS; Xu M; Figueroa ME; Dickins RA; Abdel-Wahab O; Park CY; Tsirigos A; Neel BG; Aifantis I
    Cell; 2017 Sep; 170(6):1079-1095.e20. PubMed ID: 28823558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice.
    Ko M; Bandukwala HS; An J; Lamperti ED; Thompson EC; Hastie R; Tsangaratou A; Rajewsky K; Koralov SB; Rao A
    Proc Natl Acad Sci U S A; 2011 Aug; 108(35):14566-71. PubMed ID: 21873190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
    Figueroa ME; Abdel-Wahab O; Lu C; Ward PS; Patel J; Shih A; Li Y; Bhagwat N; Vasanthakumar A; Fernandez HF; Tallman MS; Sun Z; Wolniak K; Peeters JK; Liu W; Choe SE; Fantin VR; Paietta E; Löwenberg B; Licht JD; Godley LA; Delwel R; Valk PJ; Thompson CB; Levine RL; Melnick A
    Cancer Cell; 2010 Dec; 18(6):553-67. PubMed ID: 21130701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tet2 restrains inflammatory gene expression in macrophages.
    Cull AH; Snetsinger B; Buckstein R; Wells RA; Rauh MJ
    Exp Hematol; 2017 Nov; 55():56-70.e13. PubMed ID: 28826859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dysregulation of TET2 in hematologic malignancies.
    Chiba S
    Int J Hematol; 2017 Jan; 105(1):17-22. PubMed ID: 27848178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia.
    Guan Y; Hasipek M; Jiang D; Tiwari AD; Grabowski DR; Pagliuca S; Kongkiatkamon S; Patel B; Singh S; Parker Y; LaFramboise T; Lindner D; Sekeres MA; Mian OY; Saunthararajah Y; Maciejewski JP; Jha BK
    J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35085104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-Associated
    Ferrone CK; Blydt-Hansen M; Rauh MJ
    Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TET proteins and 5-methylcytosine oxidation in hematological cancers.
    Ko M; An J; Pastor WA; Koralov SB; Rajewsky K; Rao A
    Immunol Rev; 2015 Jan; 263(1):6-21. PubMed ID: 25510268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A zebrafish model of myelodysplastic syndrome produced through tet2 genomic editing.
    Gjini E; Mansour MR; Sander JD; Moritz N; Nguyen AT; Kesarsing M; Gans E; He S; Chen S; Ko M; Kuang YY; Yang S; Zhou Y; Rodig S; Zon LI; Joung JK; Rao A; Look AT
    Mol Cell Biol; 2015 Mar; 35(5):789-804. PubMed ID: 25512612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.